Retraction: Hydrophilic Prodrug Approach for Reduced Pigment Binding and Enhanced Transscleral Retinal Delivery of Celecoxib (Molecular Pharmaceutics (2012) 9: 3 (605−614) DOI: 10.1021/mp2005164);Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib

Molecular Pharmaceutics

Volumn 9, Issue 3, 2012, Pages 605-614

  Malik, Pradip ^a   Kadam, Rajendra S ^b   Cheruvu, Narayan P S ^a   Kompella, Uday B ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

celecoxib; melanin binding; prodrugs; retinal delivery; transscleral

Indexed keywords

AMIDASE; CELECOXIB; CELECOXIB ACETAMIDE; CELECOXIB MALEAMIDIC ACID; CELECOXIB SUCCINAMIDIC ACID; CYTOCHROME P450; ESTERASE; MELANIN; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; COW; CYTOTOXICITY TEST; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; LENS; LIPOPHILICITY; MALE; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RAT; RETINA; SCLERA; TISSUE DISTRIBUTION; VITREOUS BODY;

EID: 84858017415     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00366     Document Type: Erratum

References (45)

1. Amrite, A.; Pugazhenthi, V.; Cheruvu, N.; Kompella, U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes Expert Opin. Drug Delivery 2010, 7 (5) 631-45
2. Lamoureux, E. L.; Hassell, J. B.; Keeffe, J. E. The impact of diabetic retinopathy on participation in daily living Arch. Ophthalmol. 2004, 122 (1) 84-8 (Pubitemid 38063610)
3. Congdon, N.; O'Colmain, B.; Klaver, C. C.; Klein, R.; Munoz, B.; Friedman, D. S.; Kempen, J.; Taylor, H. R.; Mitchell, P. Causes and prevalence of visual impairment among adults in the United States Arch. Ophthalmol. 2004, 122 (4) 477-85 (Pubitemid 38456282)
4. Mohamed, Q.; Gillies, M. C.; Wong, T. Y. Management of diabetic retinopathy: a systematic review JAMA, J. Am. Med. Assoc. 2007, 298 (8) 902-16 (Pubitemid 47311296)
5. Rao, V. R.; Prescott, E.; Shelke, N. B.; Trivedi, R.; Thomas, P.; Struble, C.; Gadek, T.; O'Neill, C. A.; Kompella, U. B. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) Invest. Ophthalmol. Vis. Sci. 2010, 51 (10) 5198-204
6. Blumenkranz, M. S. Optimal current and future treatments for diabetic macular oedema Eye (London) 2010, 24 (3) 428-34
7. Sennlaub, F.; Valamanesh, F.; Vazquez-Tello, A.; El-Asrar, A. M.; Checchin, D.; Brault, S.; Gobeil, F.; Beauchamp, M. H.; Mwaikambo, B.; Courtois, Y.; Geboes, K.; Varma, D. R.; Lachapelle, P.; Ong, H.; Behar-Cohen, F.; Chemtob, S. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy Circulation 2003, 108 (2) 198-204 (Pubitemid 36871303)
8. Wilkinson-Berka, J. L. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide Curr. Pharm. Des. 2004, 10 (27) 3331-48 (Pubitemid 39276620)
9. Callanan, D.; Williams, P. Topical nepafenac in the treatment of diabetic macular edema Clin. Ophthalmol. 2008, 2 (4) 689-92
10. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, Gd; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib) J. Med. Chem. 1997, 40 (9) 1347-65 (Pubitemid 27198082)
11. Pasinetti, G. M. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions J. Neurosci. Res. 1998, 54 (1) 1-6 (Pubitemid 28447183)
12. Subbaramaiah, K.; Zakim, D.; Weksler, B. B.; Dannenberg, A. J. Inhibition of cyclooxygenase: a novel approach to cancer prevention Proc. Soc. Exp. Biol. Med. 1997, 216 (2) 201-10
13. Steinbach, G.; Lynch, P. M.; Phillips, R. K.; Wallace, M. H.; Hawk, E.; Gordon, G. B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L. K.; Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N. Engl. J. Med. 2000, 342 (26) 1946-52 (Pubitemid 30419089)
14. Clemett, D.; Goa, K. L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain Drugs 2000, 59 (4) 957-80 (Pubitemid 30232330)
15. Benezra, D. Ocular inflammation: basic and clinical concepts; Martin Dunitz: London, 1999; p xiv, 512 pp.
16. Amrite, A. C.; Ayalasomayajula, S. P.; Cheruvu, N. P.; Kompella, U. B. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage Invest. Ophthalmol. Visual Sci. 2006, 47 (3) 1149-60 (Pubitemid 46768351)
17. Ayalasomayajula, S. P.; Kompella, U. B. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model Eur. J. Pharmacol. 2003, 458 (3) 283-9 (Pubitemid 36009467)
18. Ayalasomayajula, S. P.; Kompella, U. B. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model Eur. J. Pharmacol. 2005, 511 (2 - 3) 191-8 (Pubitemid 40417726)
19. Chew, E. Y.; Kim, J.; Coleman, H. R.; Aiello, L. P.; Fish, G.; Ip, M.; Haller, J. A.; Figueroa, M.; Martin, D.; Callanan, D.; Avery, R.; Hammel, K.; Thompson, D. J.; Ferris, F. L., 3rd. Preliminary assessment of celecoxib and microdiode pulse laser treatment of diabetic macular edema Retina 2010, 30 (3) 459-67
20. Ayalasomayajula, S. P.; Kompella, U. B. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration Pharm. Res. 2004, 21 (10) 1797-804 (Pubitemid 39390091)
21. Kompella, U. B.; Kadam, R. S.; Lee, V. H. Recent advances in ophthalmic drug delivery Ther. Delivery 2010, 1 (3) 435-56
22. Kompella, U. B.; Bandi, N.; Ayalasomayajula, S. P. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression Invest. Ophthalmol. Visual Sci. 2003, 44 (3) 1192-201 (Pubitemid 36297840)
23. Higuchi, T.; Stella, V. J. Pro-drugs as novel drug delivery systems; American Chemical Society: Washington, DC, 1975; p ix, 245 pp.
24. Stella, V., A Case for Prodrugs. In Prodrugs, Challenges and Rewards Part 1; AAPS Press/Springer: New York, 2007; pp 3-33.
25. Cheruvu, N. P.; Kompella, U. B. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer Invest. Ophthalmol. Visual Sci. 2006, 47 (10) 4513-22 (Pubitemid 46579380)
26. Cheruvu, N. P.; Amrite, A. C.; Kompella, U. B. Effect of eye pigmentation on transscleral drug delivery Invest. Ophthalmol. Visual Sci. 2008, 49 (1) 333-41
27. Kadam, R. S.; Kompella, U. B. Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve J. Pharmacol. Exp. Ther. 2010, 332 (3) 1107-20
28. Kadam, R. S.; Cheruvu, N. P.; Edelhauser, H. F.; Kompella, U. B. Sclera-Choroid-RPE Transport of Eight {beta}-Blockers in Human, Bovine, Porcine, Rabbit, and Rat Models Invest. Ophthalmol. Visual Sci. 2011, 52 (8) 5387-99
29. Leblanc, B.; Jezequel, S.; Davies, T.; Hanton, G.; Taradach, C. Binding of drugs to eye melanin is not predictive of ocular toxicity Regul. Toxicol. Pharmacol. 1998, 28 (2) 124-32 (Pubitemid 29076778)
30. Zane, P. A.; Brindle, S. D.; Gause, D. O.; O'Buck, A. J.; Raghavan, P. R.; Tripp, S. L. Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses Pharm. Res. 1990, 7 (9) 935-41 (Pubitemid 20349766)
31. Qandil, A. M.; El Mohtadi, F. H.; Tashtoush, B. M. Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides Int. J. Pharm. 2011, 416 (1) 85-96
32. Wen, H.; Hao, J.; Li, S. K. Influence of permeant lipophilicity on permeation across human sclera Pharm. Res. 2010, 27 (11) 2446-56
33. Maurice, D. M.; Ota, Y. The kinetics of subconjunctival injections Jpn. J. Ophthalmol. 1978, 22, 95-100 (Pubitemid 8338836)
34. Maurice, D. M. Drug delivery to the posterior segment from drops Surv. Ophthalmol. 2002, 47 (Suppl. 1) S41-52
35. Lee, T. W.; Robinson, J. R. Drug delivery to the posterior segment of the eye II: development and validation of a simple pharmacokinetic model for subconjunctival injection J. Ocul. Pharmacol. Ther. 2004, 20 (1) 43-53 (Pubitemid 38199331)
36. Talley, J. J.; Bertenshaw, S. R.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Kellogg, M. S.; Koboldt, C. M.; Yuan, J.; Zhang, Y. Y.; Seibert, K. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration J. Med. Chem. 2000, 43 (9) 1661-3 (Pubitemid 30304998)
37. Mamidi, R. N.; Mullangi, R.; Kota, J.; Bhamidipati, R.; Khan, A. A.; Katneni, K.; Datla, S.; Singh, S. K.; Rao, K. Y.; Rao, C. S.; Srinivas, N. R.; Rajagopalan, R. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats Biopharm. Drug Dispos. 2002, 23 (7) 273-82 (Pubitemid 35203427)
38. Morgan, P. H.; Nair, I. G. Hydrolysis of a synthetic amide substrate by human C1 esterase (C1s) J. Immunol. 1977, 119 (1) 19-25 (Pubitemid 8141111)
39. Peng, H. M.; Raner, G. M.; Vaz, A. D.; Coon, M. J. Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450 Arch. Biochem. Biophys. 1995, 318 (2) 333-9
40. Miyata, N.; Taniguchi, K.; Seki, T.; Ishimoto, T.; Sato-Watanabe, M.; Yasuda, Y.; Doi, M.; Kametani, S.; Tomishima, Y.; Ueki, T.; Sato, M.; Kameo, K. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme Br. J. Pharmacol. 2001, 133 (3) 325-9 (Pubitemid 33027767)
41. Sarich, T. C.; Adams, S. P.; Petricca, G.; Wright, J. M. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor J. Pharmacol. Exp. Ther. 1999, 289 (2) 695-702 (Pubitemid 29191221)
42. Lamango, N. S. Liver prenylated methylated protein methyl esterase is an organophosphate-sensitive enzyme J. Biochem. Mol. Toxicol. 2005, 19 (5) 347-57 (Pubitemid 41654269)
43. Kadam, R. S.; Jadhav, G.; Ogidigben, M.; Kompella, U. B. Ocular Pharmacokinetics of Dorzolamide and Brinzolamide Following Single and Multiple Topical Dosing: Implications for Effects on Ocular Blood Flow Drug Metab. Dispos. 2011, 39, 1529-1537
44. Thakur, A.; Kadam, R. S.; Kompella, U. B. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids Drug Metab. Dispos. 2011, 39 (5) 771-81
45. Amrite, A. C.; Kompella, U. B. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism J. Pharmacol. Exp. Ther. 2008, 324 (2) 749-58 (Pubitemid 351185844)